Table 3.
Short-term effect on pain (day 1)
| All patients (n = 30) | CP (n = 11) | PDAC (n = 19) | ||||||||||
| Baseline | 1 d | Mean differencea | N patients response (%) | Baseline | 1 d | Mean differencea | N patients response (%) | Baseline | 1 d | Mean difference | N patients response (%) | |
| Mean score BPI (SD)b | ||||||||||||
| Severity of pain 0-10 (mean) | 5.9 (1.6) | 4.9 (2.4) | −0.8 (1.5) | 9/29 (31%) | 5.8 (1.9) | 4.6 (2.5) | −1.1 (1.3) | 2/11 (18%) | 6.1 (1.1) | 5.6 (2.1) | −0.5 (1.7) | 7/18 (39%) |
| Pain interference 0–10 (mean) | 5.6 (2.4) | 4.6 (2.5) | −0.9 (1.1) | 10/28 (36%) | 5.4 (2.5) | 4.0 (2.8) | −1.2 (0.8) | 2/11 (18%) | 6.0 (2.2) | 5.5 (2.0) | −0.5 (1.4) | 8/17 (47%) |
| Numeric rating scale | ||||||||||||
| Average pain (0–10) | 6.3 (1.7) | 5.8 (1.9) | −0.5 (1.1) | 5/30 (17%) | 6.0 (1.9) | 5.6 (2.1) | −0.4 (1.2) | 2/11 (13%) | 6.7 (1.3) | 6.1 (1.4) | −0.6 (0.9) | 3/19 (16%) |
| Worst pain (0–10) | 8.1 (1.6) | 7.5 (1.8) | −0.6 (0.9) | 5/30 (17%) | 7.9 (1.6) | 7.4 (1.8) | −0.6 (0.9) | 2/11 (13%) | 8.3 (1.5) | 7.7 (1.9) | −0.6 (0.9) | 3/19 (16%) |
| Izbicki pain score (0–100)c | NA | NA | NA | NA | 75.5 (17.4) | 73.9 (12.1) | 1.6 (12.6) | 1/10 (10%) | NA | NA | NA | NA |
| Global perceived effect | ||||||||||||
| Recovery of complaints (1–7) | NA | 3.4 (0.9) | NA | 5/30 (17%) | NA | 3.4 (0.9) | NA | 2/11 (18%) | NA | 4.0 (1.0) | NA | 3/19 (16%) |
| Treatment satisfaction (1–7) | 2.7 (1.4) | 16/30 (53%) | 2.9 (1.5) | 7/11 (64%) | 2.5 (1.2) | 1/19 (47%) | ||||||
No missing values unless indicated otherwise.
BPI, Brief Pain Inventory; CP, chronic pancreatitis; NA, not applicable; PDAC, pancreatic ductal adenocarcinoma.
a
Clinically relevant response was defined as Δ < −1.3.
b
One patient missing in BPI, severity of pain, and 2 patients in BPI, pain interference (both PDAC groups).
c
One patient missing.